Yahoo Finance

Boehringer to expand oncology presence with $572m Tessellate Bio deal

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...
Yahoo Finance

Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer

NAARDEN, the Netherlands and STEVENAGE, United Kingdom, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, ...
manilatimes

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer

AMSTERDAM and STEVENAGE, United Kingdom, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today ...
Pharmabiz

Tessellate BIO, Omico & CMRI collaborate to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian paediatric medical research ...
Pharmabiz

Boehringer Ingelheim & Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Boehringer Ingelheim, is a biopharmaceutical company, and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research ...
PharmiWeb

Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a ...